Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

NCT04376866 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

204

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Nasopharyngeal Carcinoma

Interventions

DRUG: Toripalimab

Sponsor

Cancer Hospital of Guangxi Medical University